Mesoblast (MESO) - 2024 Q2 - Earnings Call Presentation

Global Leader in Allogeneic Cellular Medicines | --- | --- | |----------------------------------------------|-------| | | | | | | | for Inflammatory Diseases | | | Financial Results and Operational Update for | | | the Half-Year Ended December 31, 2023 | | February 2024 This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity ...